Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Blood ; 123(12): 1836-49, 2014 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-24452203

RESUMO

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone genetics and the recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic relevance. We show that the quality of the BM stromal meshwork of SMZL infiltrates correlates with time to progression. In particular, we describe the unfavorable prognostic influence of dense CD40 expression by BM stromal cells, which involves the contribution of CD40 ligand (CD40L)-expressing bystander mast cells infiltrating SMZL BM aggregates. The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the SMZL microenvironment finds correlation in p53(-/-) mice developing SMZL and contributes to the engendering of detrimental proinflammatory conditions. Our study highlights a dynamic interaction, playing between nonneoplastic elements within the SMZL niche, toward disease progression.


Assuntos
Antígenos CD40/metabolismo , Linfoma de Zona Marginal Tipo Células B/imunologia , Linfoma de Zona Marginal Tipo Células B/patologia , Mastócitos/imunologia , Mastócitos/patologia , Células-Tronco Mesenquimais/imunologia , Células-Tronco Mesenquimais/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Linfócitos B/imunologia , Linfócitos B/patologia , Ligante de CD40/metabolismo , Diferenciação Celular , Proliferação de Células , Citocinas/biossíntese , Progressão da Doença , Intervalo Livre de Doença , Feminino , Genes p53 , Humanos , Mediadores da Inflamação/metabolismo , Linfoma de Zona Marginal Tipo Células B/etiologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Pessoa de Meia-Idade , Prognóstico , Microambiente Tumoral/imunologia
2.
Leuk Lymphoma ; 55(11): 2457-65, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24506469

RESUMO

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma a mostly incurable disease. Moreover, we provide a new insight into the crosstalk between HSTL clones and the bone marrow, liver and spleen vascular microenvironment, in which neoplastic cells reside and proliferate. We further discuss γδ-HSTL associated molecules that might be proposed as potential targets for novel therapeutic approaches.


Assuntos
Neoplasias Hepáticas/patologia , Linfoma de Células T Periférico/patologia , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Neoplasias Esplênicas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Humanos , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/terapia , Linfoma de Células T Periférico/metabolismo , Linfoma de Células T Periférico/terapia , Neoplasias Esplênicas/metabolismo , Neoplasias Esplênicas/terapia , Transplante de Células-Tronco/métodos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA